COVID-19 Clinical Trial
Official title:
Emergency Laparotomies and Outcomes During the COVID-19 Pandemic - a Retrospective Cohort Study
NCT number | NCT04419571 |
Other study ID # | 133196 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 23, 2020 |
Est. completion date | June 16, 2020 |
Verified date | July 2020 |
Source | Barking, Havering and Redbridge University Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
NLR has previously been observed to correlate with complications in upper GI (1) and
colorectal (2) surgery. The investigators sought to assess if a similar correlation can be
identified in emergency general surgical patients and if the presence of suspected or
confirmed COVID-19 may impact on this.
Given the heterogeneity of emergency general surgery the investigators therefore plan to
perform a retrospective review of patients having emergency laparotomies only at a single NHS
site during COVID-19 pandemic. Assessment of outcomes and Neutrophil:lymphocyte ratio as a
predictor of outcomes will be completed. Outcomes will be completed in line with the recent
COVIDSurg study criteria (3). The primary outcome is 30-day mortality. Secondary outcomes are
7-day mortality, re-operation, length of stay, post-operative respiratory failure,
post-operative ARDS (Acute Respiratory Distress Syndrome), post-operative sepsis and ITU
(Intensive Therapy Unit)/HDU (High Dependency Unit) admission.
Status | Completed |
Enrollment | 94 |
Est. completion date | June 16, 2020 |
Est. primary completion date | June 16, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients undergoing emergency laparotomy (change made due to heterogeneity of emergency general surgery) Exclusion Criteria: - Inherited or acquired immunodeficiency (which may directly skew NLR) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen's Hospital | Romford |
Lead Sponsor | Collaborator |
---|---|
Barking, Havering and Redbridge University Hospitals NHS Trust |
United Kingdom,
Cook EJ, Walsh SR, Farooq N, Alberts JC, Justin TA, Keeling NJ. Post-operative neutrophil-lymphocyte ratio predicts complications following colorectal surgery. Int J Surg. 2007 Feb;5(1):27-30. Epub 2006 Jun 27. — View Citation
Vulliamy P, McCluney S, Mukherjee S, Ashby L, Amalesh T. Postoperative Elevation of the Neutrophil: Lymphocyte Ratio Predicts Complications Following Esophageal Resection. World J Surg. 2016 Jun;40(6):1397-403. doi: 10.1007/s00268-016-3427-z. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Other complications | Other documented post-operative complications | 30 days | |
Other | Peri-operative NLR | Neutrophil:Lymphocyte Ratio will be recorded daily in the peri-operative period | First 3 post-operative days | |
Other | Post-operative platelet counts | Absolute platelet counts recorded daily in the peri-operative period | First 3 post-operative days | |
Other | Post-operative coagulopathy | Defined as the presence of increased PT (prothrombin time) OR APTT (activated partial thromboplastin time) OR TT (thrombin time) OR fibrinogen above 1.5X the upper limit of normal. Coagulation will either be defined as normal or abnormal for each patient if one or more of these derangement are identified. | First 3 post-operative days | |
Primary | 30-day mortality | Mortality | 30 days | |
Secondary | 7-day mortality | Mortality | 7 days | |
Secondary | Number of participants returning to theatre | Re-operation | 30 days | |
Secondary | Length of stay | Inpatient stay during index admission | 30 days | |
Secondary | Post-operative respiratory failure | Presence of respiratory failure in the post-operative period as defined in the clinical notes or discharge summaries | 30 days | |
Secondary | Post-operative ARDS | ARDS diagnosed radiologically | 30 days | |
Secondary | Post-operative sepsis | Presence of sepsis in the post-operative period as defined in the clinical notes or discharge summaries | 30 days | |
Secondary | ITU/HDU admission | ITU/HDU admission post-operatively | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|